The purpose of this research is to study the efficacy of ultrasound microvessel imaging for evaluation of Chronic Kidney Disease. Definity is an ultrasound contrast agent currently approved by the FDA for use on the heart, liver, and urinary tract. This study will look at its effectiveness on the kidney.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
186
Ultrasound contrast agent administered intravenously
Imaging technology for microvessel imaging. This technology localizes and tracks individual microbubbles (FDA approved ultrasound contrast agents) to map microvessel morphology and flow speed at a spatial resolution about 10 times higher than conventional ultrasound imaging.
Mayo Clinic Florida
Jacksonville, Florida, United States
Mayo Clinic Minnesota
Rochester, Minnesota, United States
Renal cortex microvessel density
Super-Resolution Ultrasound Imaging (SRUI) parameters reported in percentage
Time frame: Baseline
Renal cortex microvessel diameter
Super-Resolution Ultrasound Imaging (SRUI) parameters reported in millimeters (mm)
Time frame: Baseline
Renal blood flow velocity
Super-Resolution Ultrasound Imaging (SRUI) parameters reported in centimeters per second (cm/sec)
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.